Overview
I am a physician-scientist with clinical expertise in the pathologic diagnosis of genitourinary tumors including tumors of the prostate, bladder, kidney and testis. Another area of interest is gynecologic tumors. In my research laboratory we study prostate cancer, focusing on molecular mechanisms of carcinogenesis and tumor progression, as well as biomarkers, imaging and novel therapeutic strategies. In addition to patient care and research, I am also passionate about education. I have trained numerous residents, fellows, graduate students and postdocs.
Current Appointments & Affiliations
Johnston-West Distinguished Professor of Pathology
·
2018 - Present
Pathology,
Clinical Science Departments
Chair
·
2016 - Present
Pathology,
Clinical Science Departments
Professor of Pathology
·
2016 - Present
Pathology,
Clinical Science Departments
Professor of Pharmacology and Cancer Biology
·
2017 - Present
Pharmacology & Cancer Biology,
Basic Science Departments
Professor of Cell Biology
·
2022 - Present
Cell Biology,
Basic Science Departments
Member of the Duke Cancer Institute
·
2016 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Revisiting the use of CK7 and CK20 immunohistochemical stains in pathological diagnoses.
Journal Article Diagn Pathol · April 11, 2025 BACKGROUND: Cytokeratin-7 (keratin-7; CK7) and cytokeratin-20 (keratin-20; CK20) have been among the most widely used markers in pathology for prediction of tumor site of origin or classification. However, with the increased availability of newer and more ... Full text Link to item CiteTargeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone.
Journal Article Clin Cancer Res · April 1, 2025 PURPOSE: After failing primary and secondary hormonal therapy, castration-resistant and neuroendocrine prostate cancer metastatic to the bone is invariably lethal, although treatment with docetaxel and carboplatin can modestly improve survival. Therefore, ... Full text Link to item CiteSupplementary Table S1 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Other · April 1, 2025 <p>Primary antibodies used for immunohistochemistry (IHC), immunofluorescence (IF), and western blotting (WB)</p> ... Full text CiteRecent Grants
Targeting Undruggable Transcription Factor HoxB13 to Inhibit Prostate Cancer Metastasis
ResearchCo Investigator · Awarded by National Institutes of Health · 2025 - 2029Testing ATAD2 as a new therapeutic target for advanced prostate cancer
ResearchPrincipal Investigator · Awarded by University of California - Los Angeles · 2024 - 2029Elucidating alternative polyadenylation regulation during prostate cancer progression to castration-resistance
ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2029View All Grants
Education, Training & Certifications
New York University ·
1991
Ph.D.
Anhui Medical University (China) ·
1983
M.D.